Inclusion Criteria:~* Male or female (post-menopausal or surgically sterile)~* Patients with Mild to moderate
Alzheimer's disease who are receiving donepezil (AriceptÂ®) or rivastigmine transdermal system (ExelonÂ®
Patch), . Memantine (NamendaÂ®) is allowed only when prescribed in combination with donepezil or rivastigmine
transdermal system.~* Age 55 to 85 inclusive~* Patients must be living in the community~* Patients must have an
eligible informant or study partner (caregiver)~* Patients and eligible informant or study partner (caregiver)
must be able to read and understand English.~* Informed consent obtained from both the patient and the
caregiver~
